Education
About Us
Working with TipRanks
Follow Us
Collplant Holdings (CLGN)
NASDAQ:CLGN
Earnings Data
Report Date
May 22, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.37Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 26, 2025
|% Change Since: -8.93%
|Next Earnings Date:May 22, 2025
Earnings Call Sentiment|Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.Company Guidance
During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Regenerative Breast Implant Program Progress
Preclinical testing of commercial-sized breast implants (250cc) shows promising outcomes with depolarization and rapid tissue ingrowth, no complications, and maintained volume retention. This product could revolutionize breast reconstruction and aesthetic enhancements.
AbbVie Collaboration and Financial Milestone
CollPlant received a $2 million payment from AbbVie following development achievements in their dermal filler clinical trials, indicative of continued collaboration and potential future milestones.
Cash Runway Stability
Cash and cash equivalents as of December 31, 2024, were $11.9 million, with an expected operational runway through the second quarter of 2026.
---
CLGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CLGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 26, 2025 | $2.80 | $2.70 | -3.57% |
| Nov 27, 2024 | $4.26 | $4.25 | -0.23% |
| Aug 20, 2024 | $4.90 | $4.85 | -1.02% |
| May 29, 2024 | $5.95 | $5.67 | -4.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Collplant Holdings (CLGN) report earnings?
Collplant Holdings (CLGN) is schdueled to report earning on May 22, 2025, TBA Not Confirmed.
What is Collplant Holdings (CLGN) earnings time?
Collplant Holdings (CLGN) earnings time is at May 22, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLGN EPS forecast?
CLGN EPS forecast for the fiscal quarter 2025 (Q1) is -0.04.
---